Advertisement

CNS Drugs

pp 1–12 | Cite as

Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database

  • Faizan Mazhar
  • Marco Pozzi
  • Marta Gentili
  • Marco Scatigna
  • Emilio Clementi
  • Sonia RadiceEmail author
  • Carla Carnovale
Original Research Article
  • 65 Downloads

Abstract

Background

Hyponatraemia induced by antidepressant drugs is a rare but potentially life-threatening adverse reaction. Whether it is associated with all or only some antidepressant drugs is still unclear. This needs to be clarified to guide antidepressant therapies, especially in patients with electrolytic imbalances.

Objectives

The primary objective of this study was to quantify the strength of association between the use of different antidepressant drugs and hyponatraemia by using information reported to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). The secondary objective was to investigate the putative relationship between different antidepressant pharmacological targets and the risks of hyponatraemia induced by antidepressant drugs using the ‘pharmacovigilance–pharmacodynamic’ method.

Methods

We used the FAERS database to conduct a case/non-case analysis on spontaneous reports, focusing on events of hyponatraemia/syndrome of inappropriate antidiuretic hormone secretion (SIADH) reported in connection with the use of antidepressant drugs. Risk was expressed as a measure of disproportionality using the reporting odds ratio while adjusting for sex, age and concomitant medications associated with hyponatraemia/SIADH. We assessed to what extent the receptor-binding properties of antidepressant drugs could associate with the reporting odds ratios of hyponatraemia/SIADH of antidepressant drugs, building a linear regression model that included as independent variables the binding affinities (pKi) to the serotonin transporter, dopamine transporter, norepinephrine transporter, and serotonin 5-HT2C, 5-HT2A and 5-HT1A, and α1- and α2-adrenergic receptors.

Results

There were 2233 reports identified. The adjusted reporting odds ratio for the association between antidepressant drug use and hyponatraemia was 1.91 (95% confidence interval 1.83–2.00). The association was strongest for mirtazapine, followed by selective serotonin reuptake inhibitors, and lowest with serotonin-modulating antidepressant drugs. A significant linear correlation was found between the adjusted reporting odds ratios for hyponatraemia and pKi for the adrenergic receptors α1 and α2.

Conclusions

Hyponatraemia is reported at a disproportionately higher level with classes of antidepressant drugs (noradrenergic and specific serotonergic antidepressant [mirtazapine] and serotonin modulators [vortioxetine]) that are in general considered to have a better profile of tolerability in terms of hyponatraemia. With regard to the presented results, the risk of hyponatraemia with mirtazapine appears to be greater than what was reported in the literature; however, confounding by indication cannot be ruled out. Our pharmacovigilance–pharmacodynamic analysis also indicates that inhibition of the serotonin transporter may not be involved in the hyponatraemia linked to the use of antidepressant drugs.

Notes

Compliance with Ethical Standards

Funding

This study was supported by the Centre of Pharmacovigilance of Regione Lombardia (MEAP project, Monitoraggio degli eventi avversi nelle popolazioni a rischio, to Emilio Clementi) and by the Italian Ministry of Health (RC 2018 to Marco Pozzi). Faizan Mazhar is supported by the 33rd cycle Ph.D. programme in “Scienze Farmacologiche Sperimentali e Cliniche”, Università degli Studi di Milano.

Conflict of Interest

Faizan Mazhar, Marco Pozzi, Marta Gentili, Marco Scatigna, Emilio Clementi, Sonia Radice and Carla Carnovale have no conflicts of interest that are directly relevant to the content of this article.

Supplementary material

40263_2019_631_MOESM1_ESM.docx (117 kb)
Supplementary material 1 (DOCX 116 kb)

References

  1. 1.
    Spigset O, Hedenmalm K. Hyponatraemia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug reactions. Pharmacotherapy. 1997;17(2):348–52.Google Scholar
  2. 2.
    Movig KLL, Leufkens HGM, Lenderink AW, van den Akker VGA, Hodiamont PPG, Goldschmidt HMJ, et al. Association between antidepressant drug use and hyponatraemia: a case–control study. Br J Clin Pharmacol. 2002;53(4):363–9.Google Scholar
  3. 3.
    De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatraemia: a class-by-class review of literature. Psychosomatics. 2014;55(6):536–47.Google Scholar
  4. 4.
    Mulrow CD, Williams JW Jr, Chiquette E, Aguilar C, Hitchcock-Noel P, Lee S, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med. 2000;108(1):54–64.Google Scholar
  5. 5.
    Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;2(343):d4551.Google Scholar
  6. 6.
    Leth-Moller KB, Hansen AH, Torstensson M, Andersen SE, Odum L, Gislasson G, et al. Antidepressants and the risk of hyponatraemia: a Danish register-based population study. BMJ Open. 2016;6(5):e011200.Google Scholar
  7. 7.
    Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, et al. Second-generation antidepressants and hyponatraemia risk: a population-based cohort study of older adults. Am J Kidney Dis. 2017;69(1):87–96.Google Scholar
  8. 8.
    Degner D, Grohmann R, Kropp S, Ruther E, Bender S, Engel RR, et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004;37(Suppl. 1):S39–45.Google Scholar
  9. 9.
    Letmaier M, Painold A, Holl AK, Vergin H, Engel R, Konstantinidis A, et al. Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme. Int J Neuropsychopharmacol. 2012;15(6):739–48.Google Scholar
  10. 10.
    Pelayo-Teran JM, Martinez-Perez MM, Zapico-Merayo Y. Safety in the use of antidepressants: vortioxetine-induce hyponatraemia in a case report. Rev Psiquiatr Salud Ment. 2017;10(4):219–20.Google Scholar
  11. 11.
    Jacobs GE, Cohen AF. The South London and Maudsley NHS foundation trust and Oxleas NHS foundation Trust prescribing guidelines, 9th edn. Br J Clin Pharmacol. 2008;65(4):624–5.Google Scholar
  12. 12.
    Nguyen TT, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, et al. An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017;83(3):612–22.Google Scholar
  13. 13.
    Nguyen TTH, Roussin A, Rousseau V, Montastruc JL, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: a pharmacoepidemiological-pharmacodynamic study in VigiBase®. Drug Saf. 2018;41(11):1087–96.Google Scholar
  14. 14.
    Carnovale C, Mazhar F, Pozzi M, Gentili M, Clementi E, Radice S. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database. Expert Opin Drug Saf. 2018;19:1–9.  https://doi.org/10.1080/14740338.2018.1550069.Google Scholar
  15. 15.
    US Food and Drug Administration/OpenFDA. Drug adverse events [/drug/event]. https://open.fda.gov/tools/downloads. Accessed 12 Mar 2018.
  16. 16.
    US Food and Drug Administration/OpenFDA. GitHub, Inc. 2015. https://github.com/FDA/openfda. Accessed 12 Mar 2018.
  17. 17.
    International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Medical dictionary for regulatory activities (MedDRA®). Standardised MedDRA® queries. https://www.meddra.org/standardised-meddra-queries. Accessed 12 Jan 2018.
  18. 18.
    Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819–34.Google Scholar
  19. 19.
    Madhusoodanan S, Bogunovic OJ, Moise D, Brenner R, Markowitz S, Sotelo J. Hyponatraemia associated with psychotropic medications: a review of the literature and spontaneous reports. Adverse Drug React Toxicol Rev. 2002;21(1–2):17–29.Google Scholar
  20. 20.
    Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatraemia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996;155(5):519–27.Google Scholar
  21. 21.
    Spigset O, Hedenmalm K. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf. 1995;12(3):209–25.Google Scholar
  22. 22.
    Mannesse CK, Jansen PA, Van Marum RJ, Sival RC, Kok RM, Haffmans PM, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatraemia in elderly patients treated with antidepressants: a cross-sectional study. Maturitas. 2013;76(4):357–63.Google Scholar
  23. 23.
    Greenblatt HK, Greenblatt DJ. Antidepressant-associated hyponatraemia in the elderly. J Clin Psychopharmacol. 2016;36(6):545–9.Google Scholar
  24. 24.
    Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol. 2014;170(3):G1–47.Google Scholar
  25. 25.
    Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatraemia. Am J Kidney Dis. 2008;52(1):144–53.Google Scholar
  26. 26.
    Woodward M, Gonski P, Grossmann M, Obeid J, Scholes R, Topliss DJ. Diagnosis and management of hyponatraemia in the older patient. Intern Med J. 2018;48(Suppl. 1):5–12.Google Scholar
  27. 27.
    Grattagliano I, Mastronuzzi T, D’Ambrosio G. Hyponatraemia associated with long-term medication use in the elderly: an analysis in general practice. J Prim Health Care. 2018;10(2):167–73.Google Scholar
  28. 28.
    The European Bioinformatics Institute ChEMBL database. https://www.ebi.ac.uk/chembl/. Accessed 20 Nov 2018.
  29. 29.
    British Pharmacological Society (BPS) and International Union of Basic Clinical Pharmacology (IUPHAR). The IUPHAR/BPS guide to pharmacology. https://www.guidetopharmacology.org. Accessed 20 Nov 2018.
  30. 30.
    Psychoactive Drug Screening Program Ki Database. https://pdsp.unc.edu/databases/kidb.php. Accessed 20 Nov 2018.
  31. 31.
    The Metabolomics Innovation Centre. DrugBank. https://www.drugbank.ca. Accessed 24 Nov 2018.
  32. 32.
    Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev. 2003;55(4):597–606.Google Scholar
  33. 33.
    Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol. 2011;72(6):905–8.Google Scholar
  34. 34.
    Van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10.Google Scholar
  35. 35.
    Anderson IK, Martin GR, Ramage AG. Central administration of 5-HT activates 5-HT1A receptors to cause sympathoexcitation and 5-HT2/5-HT1C receptors to release vasopressin in anaesthetized rats. Br J Pharmacol. 1992;107(4):1020–8.Google Scholar
  36. 36.
    Thunander Sundbom L, Bingefors K, Hedborg K, Isacson D. Are men under-treated and women over-treated with antidepressants? Findings from a cross-sectional survey in Sweden. BJPsych Bull. 2017;41(3):145–50.Google Scholar
  37. 37.
    Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22(5):485–500.Google Scholar
  38. 38.
    Rochoy M, Zakhem-Stachera C, Bene J, Berkhout C, Gautier S. Antidepressive agents and hyponatraemia: a literature review and a case/non-case study in the French Pharmacovigilance database. Therapie. 2018;73(5):389–98.Google Scholar
  39. 39.
    Thomas A, Verbalis JGJCD. Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion associated with drug therapy in psychiatric patients. CNS Drugs. 1995;4(5):357–69.Google Scholar
  40. 40.
    Esposito E. Serotonin-dopamine interaction as a focus of novel antidepressant drugs. Curr Drug Targets. 2006;7(2):177–85.Google Scholar
  41. 41.
    Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113(2):296–320.Google Scholar
  42. 42.
    Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs. 2009;23(12):1003–21.Google Scholar
  43. 43.
    Pozzi M, Pineschi R, Bonanni P, Pellegri A, Clementi E. Precipitation of carbamazepine-controlled seizures due to low-dose risperidone in a child: a conspiracy to unbalance blood electrolytes. J Clin Psychopharmacol. 2016;36(6):729–30.Google Scholar
  44. 44.
    Shetty HM, Manimekalai K, Sivaprakash B, Shetty PH. Hyponatraemia secondary to antidepressant therapy: a post marketing safety study. J Pharmacovigilance. 2015;3:3.  https://doi.org/10.4172/2329-6887.1000167.Google Scholar
  45. 45.
    Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess. 2011;15(28):1–202 (iii–iv).Google Scholar
  46. 46.
    Jung YE, Jun TY, Kim KS, Bahk WM, et al. Hyponatraemia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder. Int J Clin Pharmacol Ther. 2011;49(7):437–43.Google Scholar
  47. 47.
    Roxanas M, Hibbert E, Field M. Venlafaxine hyponatraemia: incidence, mechanism and management. Aust N Z J Psychiatry. 2007;41(5):411–8.Google Scholar
  48. 48.
    Fernández EG, García DMI. Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine [abstract no. EV724]. In: Proceedings of the 24rd European Congress of Psychiatry; 12–15 Mar 2016; Madrid.Google Scholar
  49. 49.
    Lee G, Leung J. Syndrome of inappropriate secretion of antidiuretic hormone due to desvenlafaxine. Gen Hosp Psychiatry. 2013;35(5):574.e1–3.Google Scholar
  50. 50.
    Liew ED, Alderman CP. Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine. Int J Clin Pharm. 2014;36(2):253–5.Google Scholar
  51. 51.
    D’Agostino A, English CD, Rey JA. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015;40(1):36–40.Google Scholar
  52. 52.
    Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin Neurosci. 2018;72(2):64–72.Google Scholar
  53. 53.
    Seshadri M, Thalitaya MD, Simon T, Odelola C, Enow H. Antidepressants and hyponatraemia in a patient with colectomy: a case report. Psychiatr Danub. 2017;29(Suppl. 3):610–4.Google Scholar
  54. 54.
    Bagley SC, Yaeger D. Hyponatraemia associated with bupropion, a case verified by rechallenge. J Clin Psychopharmacol. 2005;25(1):98–9.Google Scholar
  55. 55.
    Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153(4):466–76.Google Scholar
  56. 56.
    Kate N, Grover S, Kumar S, Modi M. Bupropion-induced hyponatraemia. Gen Hosp Psychiatry. 2013;35(6):681.e11–682.e11.Google Scholar
  57. 57.
    Kim CS, Choi JS, Bae EH, Kim SW. Hyponatraemia associated with bupropion. Electrolyte Blood Press. 2011;9(1):23–6.Google Scholar
  58. 58.
    Munjal S, Smolin Y. Bupropion induced hyponatraemia in an elderly patient: a case report and review of the literature. Case Rep Psychiatry. 2016;2016:5103471.Google Scholar
  59. 59.
    Wiggins A, Balasubramanian T, Ferraro A. Hyponatraemia and confusion in a 70-year-old female when bupropion was added to dothiepin and escitalopram. Australas Psychiatry. 2015;23(5):507–9.Google Scholar
  60. 60.
    Pariente A, Gregoire F, Fourrier-Reglat A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891–8.Google Scholar
  61. 61.
    Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol Sci. 2004;25(4):186–92.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Faizan Mazhar
    • 1
  • Marco Pozzi
    • 2
  • Marta Gentili
    • 1
  • Marco Scatigna
    • 3
  • Emilio Clementi
    • 1
    • 2
  • Sonia Radice
    • 1
    Email author
  • Carla Carnovale
    • 1
  1. 1.Pharmacovigilance Service, Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, “Luigi Sacco” University HospitalUniversity of Milan ASST Fatebenefratelli-SaccoMilanItaly
  2. 2.Scientific Institute, IRCCS E. MedeaBosisio PariniItaly
  3. 3.Specialisation School of Clinical Pharmacology and ToxicologyUniversità di MilanoMilanItaly

Personalised recommendations